Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. - sprookjes - yvandenbroek - TriplyDB

Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.

Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.

http://www.wikidata.org/entity/Q34261526

about

Vedolizumab for induction and maintenance of remission in Crohn’s disease Vedolizumab for induction and maintenance of remission in ulcerative colitis Promising biological therapies for ulcerative colitis: A review of the literature Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease Novel Therapies for Eosinophilic Disorders Inflammatory pathways of importance for management of inflammatory bowel disease Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis Preventive health measures in inflammatory bowel disease Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.Vedolizumab for Crohn's disease.Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.Prediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseases Introducing vedolizumab to clinical practice: who, when, and how?Leukocyte Trafficking to the Small Intestine and Colon Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties.The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.Vedolizumab for the treatment of ulcerative colitis.Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?Biological therapy for ulcerative colitis: an update.Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab.Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.Emerging biologics in inflammatory bowel disease.Update on the Use of Biologic Therapy in Ulcerative Colitis.Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.Long-term Efficacy of Vedolizumab for Ulcerative Colitis.Long-term Efficacy of Vedolizumab for Crohn's Disease.New and emerging treatments for ulcerative colitis: a focus on vedolizumab.Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.Integrin α4β7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques.

P2860

Q24187571-D6F5D043-F802-4E70-BCF7-897B1C6B7483 Q24194423-A4C68E4F-2912-42A9-9988-3C781F102DFC Q26776139-377F0422-5409-4575-9D93-5BBC3F284A67 Q26786018-FE66B36F-EE59-4F37-9C5A-2350095824C2 Q26799600-76BA979F-79AF-4C49-A7C6-BB26A70D65AE Q27005445-0FC7E670-B244-4774-889E-E8C5A48E1FEE Q28067760-628EF380-9A52-4068-83B8-AA8795D37D6B Q28078112-F771EC16-5DBE-4B1F-87A3-646BBAC36E44 Q28080984-2B282A3C-DADE-44AC-8ECB-F2DB97FBA352 Q28083872-05AC1EB4-A5FA-4B4C-A559-2203380CAF00 Q28660580-0E0C1A08-B1BB-4EC7-8B47-0E8A86E8D8D9 Q30234628-E0B6907D-3D6C-48E7-9F7B-7A209D69D7A3 Q30300234-9B276010-8E0D-4880-BD15-9360053C792F Q34326912-2F1B5192-84FC-4828-BF5A-2756AC06D350 Q34635522-E76F7B90-7CF9-4FA9-85C7-F40D60A28560 Q35049579-98DAFE64-5BA5-4F81-B96C-1A5BCD5E73C0 Q35562290-634217BD-4438-414F-9AAE-8CE23EA9469F Q36592984-522FEE19-20BA-404F-8546-14E08B33C7D4 Q36783977-8513F6A6-2AA7-4827-AAF7-2B1A743909C9 Q37691599-2DADA4B0-815A-4B7C-8593-892F5E7D0233 Q37703514-3BF4734A-04F1-4243-8E47-4106B3A5EB81 Q38132555-5F25D55B-A0FB-4BBA-B375-4694701DBD9E Q38209809-1C91B06A-6576-4F99-9183-F1DA909D8FAB Q38217832-6BD8DC77-A3C5-4DA9-A029-FFA87D127099 Q38259532-4A8C5ABF-6927-41B0-8336-C04EBBC6DFFB Q38287244-6EFD5399-31C1-4BE7-9375-E0B64A49CADF Q38582914-956C6E0B-A395-4FDE-9D71-CF59D5838223 Q38608954-047A5454-18E1-4270-B43B-DDBB0EF8C64D Q38650120-C71625F0-5DAB-4410-9498-A2D857B618D7 Q38744708-FB10BE86-7DB0-4F4B-AED0-920BFCD51A0F Q39004625-69A7E456-0FBE-477C-B099-10952143ED8D Q39102244-E85D661D-B8AF-4523-8717-07ACD57800C9 Q39120032-71DB3384-25BB-4EB0-8DFB-760C505C10BA Q39317326-B001380F-8268-4689-960B-70D4A1B1E4D6 Q39340717-2AA59DE6-BAFA-4D1F-9A91-640C640441B9 Q39340730-D38ED6D5-4582-4F01-83C5-2FEF8B30A621 Q41149278-46B22819-8D72-440C-86DD-15048DCDC864 Q42364630-F8B8BFE7-E6C4-4A60-AEAE-E7E854781E4C Q47109861-0F729E7D-A5BE-470F-99F9-25F14A0DBAB1 Q47381745-BF072AD6-A283-4959-89AB-30E86B481F0B

P2860

Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.

http://www.wikidata.org/entity/Q34261526

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Exclusive antagonism of the α4 ...... y of this pathway in primates.

@ast

Exclusive antagonism of the α4 ...... y of this pathway in primates.

@en

Exclusive antagonism of the α4 ...... y of this pathway in primates.

@nl

type

label

Exclusive antagonism of the α4 ...... y of this pathway in primates.

@ast

Exclusive antagonism of the α4 ...... y of this pathway in primates.

@en

Exclusive antagonism of the α4 ...... y of this pathway in primates.

@nl

prefLabel

Exclusive antagonism of the α4 ...... y of this pathway in primates.

@ast

Exclusive antagonism of the α4 ...... y of this pathway in primates.

@en

Exclusive antagonism of the α4 ...... y of this pathway in primates.

@nl

P1433

Q34261526-9631E3E0-DA28-4090-9564-2BF984764CAF

P1476

Q34261526-B5A6F18C-A845-4C4E-B785-D06C0401F526

P2093

Q34261526-2A250DFE-B8FF-4FB4-8E9A-558B2779371C

Q34261526-3FC91AD1-EC14-406D-B02C-E449A8AE6782

Q34261526-612A0917-52CF-4FD3-AE5F-FF8A23DBDADD

Q34261526-78774083-7261-4A24-8417-E12F2773662A

Q34261526-AB4B2E46-3A30-4716-82AD-494D4C6FD47D

Q34261526-CB0625C0-4855-46F8-99C0-558538B31758

Q34261526-F8BC4EC8-9A04-4E4A-B303-A611F3BCBD05

P2860

Q34261526-092F1B7A-2F1C-499C-88F0-21B2D86511E7

Q34261526-0B478E9D-A0C0-4F46-8408-67A322437B24

Q34261526-3319D1A4-28AF-4790-A0F8-24F863B4F785

Q34261526-337DC7ED-C796-40BE-826B-F437F5A10DF2

Q34261526-3894087B-C38D-4411-BF3A-49571E0035DE

Q34261526-4D421B84-A004-4558-BD7B-140B09973E3D

Q34261526-6302471A-C794-4A70-B490-D4B922133BE1

Q34261526-72465AC7-DE93-4617-BB91-2053287C53D2

Q34261526-765A7A5C-940D-466B-99AF-718217B0A398

Q34261526-81D3E73F-3A82-413D-BE80-032A4F060E28

P304

Q34261526-9BE26AA2-54FA-4265-94C8-66F99C7AA7A9

P31

Q34261526-061D4417-3201-4AF7-A375-DF4B6ADD8EF6

P356

Q34261526-5F134A2E-1E75-40E8-B8BD-DD1544793DF3

P433

Q34261526-0AEF2BEB-D0C8-4633-975C-5F39E90070CF

P478

Q34261526-39938D48-0965-4044-AED5-479E1C0A3D57

P577

Q34261526-EBD79C21-DBB2-4B4F-B35C-1C3E4250BD1F

P5875

Q34261526-0883B087-469A-403D-9FF0-89CDFB694C10

P698

Q34261526-6193FB18-4C37-4DBF-828A-21FAD2CA82B5

P356

P1433

Inflammatory Bowel Diseases

P1476

Exclusive antagonism of the α4 ...... y of this pathway in primates.

@en

P2093

Eric R Fedyk

http://www.w3.org/2001/XMLSchema#string

Hua Yang

http://www.w3.org/2001/XMLSchema#string

Kristine Burke

http://www.w3.org/2001/XMLSchema#string

Li-Li Yang

http://www.w3.org/2001/XMLSchema#string

Tim Wyant

http://www.w3.org/2001/XMLSchema#string

Vilmos Csizmadia

http://www.w3.org/2001/XMLSchema#string

Vivek J Kadambi

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Natalizumab for active Crohn's disease

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

Unravelling the pathogenesis of inflammatory bowel disease

Distinct changes in adult lymphopoiesis in Rag2-/- mice fully reconstituted by alpha4-deficient adult bone marrow cells.

Tissue-tropic effector T cells: generation and targeting opportunities.

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

P304

2107-2119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IBD.22940

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221703754

http://www.w3.org/2001/XMLSchema#string

P698

22419649

http://www.w3.org/2001/XMLSchema#string